该药于2005年获批上市以后,新基将沙利度胺的策略照搬在它的身上,也对其安全管理方案(REMS)和潜在临床用法申请了一系列的专利。在具体的销售中,新基授权McKesson作为其RevAssist项目的独家代理来发售Revlimid。于是,新基再一次将竞争者有力地拦截在外。基于明显的疗效和有力的销售,Revlimid成为了历史上最畅销的小...
Welcome to the REMS Programs Administered by Bristol Myers Squibb To avoid embryo-fetal exposure, Risk Evaluation and Mitigation Strategy (REMS) programs are mandatory for the REMS products THALOMID® (thalidomide), POMALYST® (pomalidomide), REVLIMID® (lenalidomide) and generic lenalidomide. The...